{'fraction_non_alphanumeric': 0.033341714860447576, 'fraction_numerical': 0.03303997988433493, 'mean_word_length': 4.876477541371158, 'pattern_counts': {'":': 0, '<': 7, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Apoptotic effect of astaxanthin from white shrimp shells on lung cancer A549 cells

Purpose: To investigate the anti-cancer potential of astaxanthin from Litopenaeus vannamei encapsulated in liposomes (ASX) to treat lung cancer A549 cells. Methods: Lung adenocarcinoma A549 cells were cultured and treated with ASX, following which cell viability and nuclear staining were performed. Generation of ROS was identified by the DCFH-DA assay while tetramethylrhodamine ethyl ester was used to determine the mitochondrial membrane potential. Flow cytometry was applied to investigate caspase-3/7 activity and cell cycle distribution. Results: ASX inhibited growth of A549 in a concentrationand timedependent manner. The IC50 values at 24, 48 and 72 h were 53.73, 22.85, 17.46 μg/mL, respectively (p < 0.05). After incubation with ASX, the morphological changes were observed in A549 cells following Hoechst 33342/PI fluorescent staining. ASX increased ROS generation and was associated with the collapse of mitochondrial membrane potential, which subsequently triggered the activation of caspase-3/7 activity leading to apoptosis (p < 0.05). In addition, A549 cells accumulated in the G0/G1 phase. Conclusion: The results suggest that ASX is a valuable nutraceutical agent to target A549 lung cancer cells via ROS-dependent pathway as well as blockage of cell cycle progression.


INTRODUCTION
Lung cancer is one of the major diseases worldwide, the third leading cause of cancerrelated death after breast cancer and prostate cancer. To date, the cause of lung cancer is no longer limited to tobacco smoking. Other contributing factors including diet and food supplements, physical activity, air pollution, have been identified in non-smokers. Epidemiological studies have indicated non-small cell lung cancer (NSCLC) to be the predominant type of lung cancer.
Current treatments for NSCLC patients are surgery and adjuvant therapy which may include radiation and chemotherapy. Major toxicities including neutropenia, peripheral neuropathy, nausea and vomiting, nephrotoxicity present as major side effects after chemotherapy [1]. Thus, to develop a potent cancer therapeutic agent with low toxicities and fewer side effects would be desirable. Furthermore, there is an obvious link between diets and human cancers. A number of naturally-occurring substances from antioxidantrich foods are proven to possess a potential role in cancer therapy [2].
Astaxanthin, a potent carotenoid rich with antioxidant activity, mostly found in crustacean shells (e.g. shrimps and crabs), algae, and other marine organisms [3]. In addition to its excellent antioxidant activity, astaxanthin has been reported to possess anti-cancer effects against oral cancer, colon cancer, leukemia and hepatocellular carcinoma [4][5][6]. More recent studies reported the effects of astaxanthin on the induction of lung cancer cell cytotoxicity and amelioration of lung fibrosis [7,8], thereby drawing a considerable attention.
It has been reported that astaxanthin extracted from the shell of Arabian red shrimp Aristeus alcocki showed a more powerful antioxidant activity than the extract from the green microalgae Haematococcus pluvialis [9]. In addition, free astaxanthin from Litopenaeus vannamei demonstrated a higher percentage (32.95 %) of anti-oxidant activity than that from Haematococcus pluvialis (5 %) [10].
Nevertheless, the potential use of astaxanthin is often limited due to poor water solubility as well as low bioavailability after oral administration and susceptibility to thermal degradation. These obstacles continue to limit on its therapeutic application in aqueous-based system [11]. Thus, the encapsulation of astaxanthin in nanoliposome, whose structure resembles the lipid membrane of living cells, as carrier system would preserve the native properties of astaxanthin as well as provide its stable aqueous dispersion thus improve its therapeutic potential [12]. Therefore, the present study aimed to investigate the in vitro anti-cancer effects of astaxanthin extracted from white shrimp shells Litopenaeus vannamei and encapsulated in liposomes (ASX) as well as its ability to induce apoptosis and cause cell cycle arrest in human NSCLC A549 cells.

Preparation of liposomes containing astaxanthin from white shrimp shells
Shells of fresh white shrimp (Litopenaeus vannamei) were obtained from a frozen shrimp processing plant in Samut-Sakorn province, Thailand. The shells were then transported to the laboratory within two hours in a cool-Styrofoam box. Astaxanthin was extracted as previously described [13]. To explain briefly, shrimp shells were mixed with ethanol at a ratio of 1:2 in a blender and filtered to collect the extract. The process was repeated three times. Solvent was removed inside a vacuum at 40 ºC, 175 MPa using a rotary evaporator to obtain the concentrated extract. Astaxanthin loaded in liposome was prepared by the thin-film hydration method [13]. Phospholipids (70% PC) was dissolved in ethanol (2.0 %w/v), then astaxanthin (2.0 %w/v) was added. After dissolution, the solution was evaporated in a vacuum at 40 °C. The obtained lipid film was hydrated with water, followed by using an ultrasonic atomizer to obtain the liposome. The sample was stored in the refrigerator (at 4 ๐ C) until use.

Cell culture
Cancer cell lines of human non-small cell lung cancer A549 were purchased from Cell Lines Service (CLS, Eppelheim, Germany) and was grown in Ham's F-12K medium supplemented with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin, and maintained in a humidified atmosphere at 37ºC in 5% CO2. The growth medium was replaced twice a week. After reaching confluence, 0.25% trypsin/EDTA was used to subculture.

Cell viability assay
Cell viability was determined using MTT assay, which relies on the reduction of yellow tetrazolium salt into purple formazan crystals by mitochondrial dehydrogenases enzymes of viable cells. Briefly, A549 cells were seeded in 96-well culture plates (1 x 10 4 cells/well). After 24 h incubation, the cells were exposed to different concentrations of ASX and cisplatin for 24, 48, 72 h, respectively. Then 100 µL of MTT reagent (0.5 mg/mL) was added and incubated for 2 h at 37ºC. After removing the supernatant, 100 µl of DMSO was added to dissolve the precipitate formazan crystals. The optical density (OD) values were then measured with the microplate reader (BioTek, Highland Park, USA) using 570 nm reference wavelength, and the IC50 values were determined by CompuSyn software.

Hoechst 33342/PI staining and morphological observation
Apoptosis nuclear morphology was fluorescently probed by Hoechst 3342/PI staining. A549 cells were cultured in 6-well plates (1 x 10 4 cells/well) and treated with 25, 50, and 100 µg/mL ASX and cisplatin. Following exposure for 24 h, the cells were double-stained with 10 µg/mL Hoechst 33342 and 2 µg/mL PI for 30 min in the dark. The cells were washed with PBS and observed under an inverted fluorescence microscope (Nikon ECLIPSE Ti, Kanagawa, Japan) with excitation at 360 nm and emission at 465 nm.

Assessment of intracellular reactive oxygen species (ROS)
Cells treated with 50 µg/mL ASX and cisplatin were grown on 6-well plates in order to quantify the accumulation of intracellular ROS based on the detection of cell permeable DCFH-DA into fluorescent dichlorofluorescein (DCF). After 2 and 4 h of incubation, the cells were stained with 20 µM DCFH-DA for 1 h at 37°C in the dark. After removing the solution, 100 µl/well of PBS was added and the fluorescent intensity then measured with a fluorescence microplate reader (BioTek, Highland Park, USA) at excitation 485 nm and emission 530 nm.

Assessment of the alterations of mitochondrial membrane potential (MMP)
Mitochondrial membrane potential was performed using TMRE mitochondrial membrane potential assay kit (Abcam, Ab113852) in order to label the active mitochondria. A549 cells were cultured and treated with 50 µg/mL ASX and cisplatin. Subsequently, the cells were stained with TMRE at 37 ºC for 20 min in the dark and the TMRE intensity was fluorescently analyzed by a fluorescence microplate reader with an excitation of 549 nm and emission of 575 nm (BioTek, Highland Park, USA).

Caspase-3/7 activity assay
A549 cells were plated at 1 x 10 6 cells/mL and were allowed to adhere for 24 h. After the cells were incubated with or without ASX, caspase-3/7 activity was evaluated by Muse Caspase-3/7 assay kit (Merck, MCH100108). The Muse caspase-3/7 working solution was added to the collected cells and incubated at 37 °C for 20 min. Prior to analyzing with a Muse® cell analyzer, 7-AAD was added and incubated at room temperature in the dark. The caspase-3/7 assay was demarcated into four quadrants representing the percentage of cells that undergo live, early apoptosis, late apoptosis, or dead.

Cell cycle analysis
Cell cycle alteration was investigated by flow cytometry assay using a Muse cell cycle kit (Merck, MCH100106). Cells were seeded at a density of 1 × 10 6 cells/mL in 6-well plates, treated with or without ASX for 24 h. After the cells were fixed with ice cold 70 % ethanol, the cells were incubated at -20°C for 4 h. Subsequently, Muse cell cycle reagent was added to the cells and incubated for 30 min at room temperature in the dark. Cell cycle distribution was then analyzed by the Muse® cell analyzer.

Statistical analysis
The results are expressed as the standard error of the mean (SEM) of at least three independent experiments. The data were analyzed by oneway ANOVA using SPSS13 software. P < 0.05 was considered to indicate statistically significant differences from the control.

Astaxanthin inhibited the growth of lung cancer A549 cells
Human non-small cell lung cancer A549 cell line was exposed to 0 -100 µg/mL of ASX for 24, 48 and 72 h and was investigated for viability using MTT assay. As shown in Figure 1 A, ASX induced concentration-and time-dependent growth inhibitory effects. The half-maximal inhibitory concentration (IC50) value at 24, 48, and 72 h was 53.73 ± 4.03, 22.85 ± 1.86, 17.46 ± 2.96 µg/mL, respectively. In addition, the viability of A549 cells treated with a positive control drug cisplatin for 24, 48, and 72 h was significantly inhibited in a concentration-and time-dependent fashion with the IC50 value of 9.54 ± 3.60, 2.96 ± 2.89, 2.09 ± 1.73 µg/mL as presented in Figure 1 B. The IC50 value obtained from ASX and cisplatin at 24 h was used for subsequent experiments.

Astaxanthin altered lung cancer A549 cell morphology
Morphological examination of cell death after treatment with ASX was investigated in this study by both phase contrast microscopy and nuclear staining with Hoechst/PI. Phase contrast microscopy revealed that ASX induced cell death in A549 cells in comparison to the untreated control (Figure 2 A). Distinctive morphological alterations including the loss of cell processes and cell contact thereby detaching from the surface of culture plates, more rounded morphology, and reduction of viable cells were observed in various concentrations of ASX (25, 50 and 100 µg/mL) and cisplatin treatment. Nuclear morphological alteration was visualized by using the blue fluorescent dye of Hoechst 33342 which selectively binds to AT region of the DNA in order to confirm the chromatin condensation of apoptotic nuclei. The red fluorescent dye of PI, which is impermeable to the viable cell membranes, was counter-stained to determine the necrosis cells. Upon treatment with 25, 50, and 100 µg/mL ASX, A549 cells demonstrated the bright blue nuclear staining of chromatin condensation and fragmentation as well as cell decrement in a concentrationdependent manner as shown in Figure 2 B. This was similar to the result obtained from cisplatin treatment. In contrast to the untreated control, the nuclei showed a typical uniformly dispersed chromatin with normal nuclear morphology. This finding validated the apoptotic characteristic of lung cancer A549 cells after treatment with ASX and cisplatin.

Astaxanthin induced ROS generation in lung cancer A549 cells
To better understand the underlying mechanism of ASX-mediated apoptosis of A549 cells, the intracellular ROS which is the key signaling molecule in apoptosis was investigated by fluorescently probing with oxidation-sensitive DCFH-DA. Treatment with IC50 of ASX and cisplatin for 4 h caused a significant increase in the intracellular ROS level (p < 0.05) as shown in Figure 3 A. In comparison with the untreated control (100%), 195 % ROS was generated in the A549 cells treated with ASX and 144 % when treated with cisplatin. However, treatment with ASX (134 %) or cisplatin (130 %) for 2 h showed no significant difference from the control of ROS generation.

Astaxanthin induced loss of mitochondrial membrane potential (MMP) in lung cancer A549 cells
To explore the possible anti-cancer role of ASX against lung cancer A549 cells associated with MMP by TMRE-labeled active mitochondria. As shown in Figure 3 B, exposure of A549 cells to ASX for 24 h triggered a significant disruption of mitochondrial membrane potential with 73 % compared to the control (p < 0.05). Cisplatin treated lung cancer A549 cells (positive control) also demonstrated a significant reduction of mitochondrial membrane potential with 69 % (p < 0.05). Our data suggested that ASX induced the loss of MMP of A549 cells via ROS-mediated pathway.

Astaxanthin induced caspase-3/7 activity in lung cancer A549 cells
The involvement of caspase-3/7 which is activated during the process of caspasedependent apoptosis was also determined. A549 cells were treated with 50 and 100 µg/ml ASX for 24 h, and caspase-3/7 activity was monitored by flow cytometry. Representative profile from flow cytometry was demonstrated into four quadrants: viable cells (lower left quadrant: caspase-3/7 -/7-AAD -), necrosis (upper left quadrant: caspase-3/7 -/7-AAD +), early apoptosis (lower right quadrant: caspase-3/7 + /7-AAD -), and late apoptosis (upper right quadrant: caspase-3/7 + /7-AAD +). Thereafter, the percentage of total apoptotic cells via caspase-3/7 activation was also quantitatively demonstrated. As shown in Figure 4 A, the untreated control A549 cells represented in a lower left quadrant indicating live cells. Upon exposing A549 cells to 50 µg/mL ASX, an increased caspase-3/7 activity in the lower and upper right quadrant were observed (Figure 4 B). By increasing the dosage of ASX to 100 µg/mL, a gradual activation of caspase-3/7 was shown in Figure 4 C. The percentage of caspase-3/7 activation by ASX was 31.26 ± 2.49 and 35.55 ± 3.70 for the concentration of 50 and 100 µg/mL ASX, respectively, and was shown to increase significantly (p < 0.05) when compared to the control, as demonstrated in Figure 4 D. As summarized in Figure 5D, the cell cycle distribution of A549 cells in G0/G1 phase after treatment with ASX (50 and 100 µg/mL) was 69.73 and 70.67 %, respectively, compared to the control (65.13 %), indicating the role of ASX induced G0/G1 phase arrest in human lung cancer A549 cells.

DISCUSSION
One major challenge of the discovery of cancer therapeutic agents is to trigger the programmed cell death or apoptosis signaling pathway. The present study used astaxanthin from Litopenaeus vannamei encapsulated in liposome to induce human NSCLC A549 cells apoptosis through ROS-dependent pathway and the blockage of cell cycle progression. First, the capacity of ASX on the growth inhibitory effect against lung cancer A549 cells was evaluated by the MTT assay. ASX demonstrated anti-cancer activity by inhibiting the growth of lung cancer cell line A549 in a concentration-and time-dependent manner, which is consistent with a recent study that reported the effect of astaxanthin on the inhibition of two NSCLC cell lines, A549 and H1703 cell viability [7].
A similar finding from Song and colleagues [5] demonstrated the potential role of astaxanthin on the inhibition of hepatocellular carcinoma CBRH-7919 cells proliferation. So, it is possible to note that the marine naturally occurring compound astaxanthin possesses as a potent cytotoxicity to the cancer cells [3,14,15]. Among the chemotherapeutic drugs targeting lung cancer, cisplatin has been employed and found to trigger lung cancer cell death [16]. Also, we reported the growth inhibitory effect of a positive control drug cisplatin against A549 cells in this study. Secondly, we verified whether the cytotoxic effect of ASX was associated with the apoptosis morphological characteristics on lung cancer cells. If cells undergo apoptosis, a series of cellular changes including cell shrinkage, nuclear fragmentation, and chromatin condensation would be observed [17]. Based on DNA-binding fluorescence staining, the brightly stained chromatin condensation and fragmentation demonstrated after ASX and cisplatin exposure in A549 cells suggest the correlation with the apoptotic morphology. However, the number of dead cells with late apoptosis or necrosis visualized by PI staining was observed in response to a high concentration of ASX (100 µg/mL) treatment.
Apoptosis is triggered by various types of stimuli either extrinsic or intrinsic signal transduction. ROS has been reported as key mediators during apoptosis machinery and is implicated in the regulation of intrinsic apoptosis pathway [17,18]. With regards to DCFH-DA assay, which probes the intracellular ROS level, we found that the accumulation of ROS in A549 cells was increased in response to the treatment with 100 µg/mL ASX and 10 µg/mL cisplatin for 4 h. The result pointed to the probability that ROS would interplay in the early event of apoptosis, which is in accordance with previous literature [19].
Further analysis also focused on mitochondria, which are a major site for ROS production as well as maintenance of cellular redox and energy homeostasis. ASX caused the disruption of MMP based on TMRE assay and subsequent activation of cysteine proteases caspase-3/7 activity. Following the disruption of mitochondrial membrane potential, the mitochondrial proapoptotic factors were released into the cytosol resulting in the formation of apoptosome which activated the executioner caspase-3/7. The activated caspase-3/7 cleaved nuclear lamin causing the breakdown of the nucleus which ultimately led to morphological and biochemical characteristic of apoptosis [20]. The present findings thus suggest the execution of apoptosis cell death via caspase-dependent mitochondrial pathway induced by ASX treatment.
Understanding the relationship between cell cycle and lung cancer as a target of antineoplastic drug is beneficial [21]. This study demonstrated ASX induced a G0/G1 phase arrest accompanied with the reduction of cells in S and G2/M phases of the cell cycle in the lung cancer A549 cells. This was in accordance with previous report examining astaxanthin from shrimp, which showed an accumulation of cells in G0/G1 phase in human breast adenocarcinoma MCF-7 cell line [22]. Cell cycle was monitored by the checkpoint proteins including the cyclin D which was the first cyclin produced in the cell cycle. The formation of cyclin D/cyclin dependent kinase (CDK) is required in DNA replication and mitosis associated with the transition of the cell cycle. Recent finding suggested that the mechanism of G0/G1 blockage might be from the downregulation of p-ERK subsequently inhibiting cyclin D1/CDK4 protein complex [23].

CONCLUSION
Taken together, the present study provides the evidence of intrinsic apoptotic signaling pathway initiated by ROS, thereby mediating mitochondrial/caspase-dependent cascade and ultimately G0/G1 cell cycle arrest in human lung cancer A549 cells by ASX treatment. Thus, ASX could be further developed as a potential chemotherapeutic agent for lung cancer in the future.